Gastrointestinal Neoplasms

Oncology
7
Pipeline Programs
7
Companies
8
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

AstraZeneca
IMFINZIApproved
durvalumab
AstraZeneca
Programmed Death Ligand-1 Blocker [EPC]injection2017

Competitive Landscape

6 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
1
DurvalumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04592913Active Not Recruiting957Est. Sep 2027
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
1
low calorie, low nitrogen parenteral nutrition for patient with NRS score 3Phase 41 trial
Active Trials
NCT00247338Completed120Est. May 2006
GSK
GSKLONDON, United Kingdom
2 programs
1
1
GSK5764227Phase 1/21 trial
IDRX-42Phase 12 trials
Active Trials
NCT07218926Recruiting450Est. Nov 2030
NCT05489237Recruiting278Est. Nov 2027
NCT06885034Recruiting320Est. Jun 2028
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 905711Phase 11 trial
Active Trials
NCT04137289Completed110Est. Nov 2023
Bristol Myers Squibb
1 program
1
BMS-582664Phase 11 trial
Active Trials
NCT00300027Terminated50
CONMED
CONMEDCO - Greenwood Village
1 program
ConMed Beamer StudyN/A1 trial
Active Trials
NCT04752670CompletedEst. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Fresenius Kabilow calorie, low nitrogen parenteral nutrition for patient with NRS score 3
GSKIDRX-42
AstraZenecaDurvalumab
GSKGSK5764227
GSKIDRX-42
Boehringer IngelheimBI 905711
Bristol Myers SquibbBMS-582664
CONMEDConMed Beamer Study

Clinical Trials (8)

Total enrollment: 2,285 patients across 8 trials

NCT00247338Fresenius Kabilow calorie, low nitrogen parenteral nutrition for patient with NRS score 3

The Impact of Low Calorie and Low Nitrogen Parenteral Nutrition Support on the Clinical Outcome of Postoperative Patients

Start: Apr 2005Est. completion: May 2006120 patients
Phase 4Completed
NCT07218926GSKIDRX-42

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Start: Dec 2025Est. completion: Nov 2030450 patients
Phase 3Recruiting
NCT04592913AstraZenecaDurvalumab

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Start: Nov 2020Est. completion: Sep 2027957 patients
Phase 3Active Not Recruiting
NCT06885034GSKGSK5764227

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

Start: Jun 2025Est. completion: Jun 2028320 patients
Phase 1/2Recruiting
NCT05489237GSKIDRX-42

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Start: Aug 2022Est. completion: Nov 2027278 patients
Phase 1Recruiting
NCT04137289Boehringer IngelheimBI 905711

A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

Start: Mar 2020Est. completion: Nov 2023110 patients
Phase 1Completed
NCT00300027Bristol Myers SquibbBMS-582664

Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies

Start: Apr 200650 patients
Phase 1Terminated
NCT04752670CONMEDConMed Beamer Study

ConMed Beamer Study

Start: May 2021Est. completion: May 2022
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4h ago

Office Administrator

SystImmune
4h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
4h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
4h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 2,285 patients
7 companies competing in this space

Related Indications

Breast Cancer(577)Prostate Cancer(385)Non-small Cell Lung Cancer(378)Multiple Myeloma(359)Cancer(249)Advanced Solid Tumors(226)Acute Myeloid Leukemia(209)Neoplasms(199)Colorectal Cancer(171)Melanoma(170)